medigraphic.com
ISSN 3061-7774 (Electronic)
ISSN 1870-7203 (Print)
Órgano Oficial del Hospital Ángeles Health System

2026, Number P5

<< Back Next >>

Acta Med 2026; 24 (P5)

Epidemiological overview of pathological terrain fractures associated with multiple myeloma in a tertiary care hospital from 2019 to 2024

Rodríguez GG, Mora RFG, Pérez FJA, Monrroy AL

Language: Spanish
References: 14
Page: 497-501
PDF size: 1418.88 Kb.


ABSTRACT

Introduction: multiple myeloma is a neoplastic disease of native B cells, characterized by the growth and accumulation of B lymphocytes and plasma cells in the bone marrow and, less frequently, in other extramedullary organs. It is the second most prevalent hematological disease, 2.12 × 100,000 people. Objective: to determine the epidemiological panorama of fractures in pathological terrain associated with multiple myeloma in the population of the General Ignacio Zaragoza Regional Hospital in the period from 2019 to 2024. Material and methods: a cross-sectional, observational, retrospective study was conducted by extracting data from the clinical records consulted, including diagnosis, fracture incidence, comorbidities, and functional capacity. Results: the most common pathological fracture location was the spine, with 46.7% (n = 28), and secondly, the femur, 28.3%. A relationship was found between the presence of comorbidities and the Karnofsky Functional Score (χ2 = 7.75, p = 0.00), and chronic kidney disease was also associated with the score (χ2 = 15.58, p = 0.03). Conclusion: the most common location was the spine, with the thoracic region being the most affected. The presence of comorbidities, specifically chronic kidney disease, negatively affects functionality, which is consistent with what has been described in the international literature.


REFERENCES

  1. Mateo-Negreira J. Fracturas vertebrales en pacientes conmieloma múltiple. Indicación y efectividad de vertebro/cifoplastias. Revisión bibliográfica. Universidad Internacional deAndalucía; 2019. Disponible en: https://dspace.unia.es/bitstream/handle/10334/3978/0916_Mateo.pdf?sequence=3

  2. Bristol-Myers S. Mieloma Múltiple: discrasia de células plasmáticas.Actualización en oncología y hematología. 2019. Disponible en:https://svfh.es/wp-content/uploads/2020/11/16.-Mieloma-multiple.-Ana-Moya.pdf.

  3. Espinoza-Zamora JR, Figueroa-Acosta R, Ledesma-Osorio Y de laC. La carga del mieloma múltiple en México: una investigaciónepidemiológica del Sistema Nacional de Salud. Gac Mex Oncol.2020; 19 (4). doi: 10.24875/j.gamo.19000281.

  4. Ramos-Peñafiel C, Madera-Maldonado C, Santoyo Sánchez A,Rojas-González E, Olarte-Carrillo I, Martínez-Tovar A et al. Mielomamúltiple: consideraciones especiales al diagnóstico. Rev ColombCancerol. 2021; 25 (2). doi: 10.35509/01239015.140.

  5. Bernstein ZS, Kim EB, Raje N. Bone disease in multiple myeloma:biologic and clinical implications. Cells. 2022; 11 (15): 2308. doi:10.3390/cells11152308.

  6. Ruiz-Alva SK, Cortes-Cerda R, Mora-Ríos FG, Benítez-RomeroA, Isunza-Ramírez A, Mejía-Rohenes LC. Tumores que producenmetástasis óseas. Acta Ortop Mex. 2021; 35 (2): 201-205. doi:10.35366/101867.

  7. Academia Nacional de Medicina de México. Consenso Mexicanode Mieloma Múltiple. Gaceta Médica de México. 2020; 156 (S2).Disponible en: https://www.gacetamedicademexico.com/portadas/gmm_20_156_supl_2.pdf

  8. Mireles-Cano JN, Escoto-Venegas E, García-González OG, Miranda-González A, González-Ramírez J, Hernández-Sepúlveda E et al. Amanagement algorithm for vertebral destruction syndrome by multiplemyeloma and metastatic spinal cord compression. Acta Ortop Mex.2020; 34 (5): 293-297. doi: 10.35366/97991.

  9. Guedes A, Becker RG, Teixeira LEM. Mieloma Múltiplo (Parte 2) -Atualizacao sobre a abordagem da doenca óssea. Rev Bras Ortop.2023; 58 (3): 368-377. doi: 10.1055/s-0043-1770150.

  10. Tanveer N, Hussein S, Pingili S, Makkena VK, Jaramillo AP, AwosusiBL et al. Multiple myeloma and the role of bisphosphonates inits management. Cureus. 2023; 15 (9): e45270. doi: 10.7759/cureus.45270.

  11. Jaramillo-García JJ, Orrego-Bustamante D, Barrios-Henao E, Martínez-Soto D. Caracterización de pacientes con mieloma múltiple yafectación de la columna vertebral atendidos en un hospital de tercernivel de Medellín, Colombia. Rev Colomb Ortop Traumatol. 2023;37 (1): e3. doi: 10.58814/01208845.3.

  12. Carrillo-Sánchez AM, de Santiago-Esquivel LA, Pérez-García CK,Antonio-Romero CE, Pérez-Zúñiga JM, Añorve-Bailon D. Localizaciónde fracturas en el mieloma múltiple en el Hospital Regional “Gral.Ignacio Zaragoza” ISSSTE. Acta Med. 2021; 19 (4): 497-500. doi:10.35366/102534.

  13. Toci GR, Bressner JA, Morris CD, Fayad L, Levin AS. Can a novelscoring system improve on the Mirels score in predicting the fracturerisk in patients with multiple myeloma? Clin Orthop Relat Res. 2021;479 (3): 521-530. doi: 10.1097/corr.0000000000001303.

  14. Timmermann C. “Just give me the best quality of life questionnaire”:the Karnofsky scale and the history of quality of life measurementsin cancer trials. Chronic Illn. 2013; 9 (3): 179-190. doi:10.1177/1742395312466903.




2020     |     www.medigraphic.com